Therapeutic targets and pharmacological mechanisms of Coptidis Rhizoma against ulcerative colitis: Findings of system pharmacology and bioinformatics analysis

Yuanming Yang(Qingdao University), Shaogang Huang(Guangzhou University of Chinese Medicine), Shumin Qin(Guangzhou University of Chinese Medicine), Haomeng Wu(Guangzhou University of Chinese Medicine), Huan Zheng(Guangzhou University of Chinese Medicine), Weihuan Chen(Guangzhou University of Chinese Medicine), Yiwei Hua(Guangzhou University of Chinese Medicine)
Frontiers in Pharmacology
November 30, 2022
10.3389/fphar.2022.1037856
Cited by 23

Related Papers

Altered metabolome and microbiome features provide clues in understanding irritable bowel syndrome and depression comorbidity
|The ISME Journal|2021|120
Biomarkers prediction and immune landscape in ulcerative colitis: Findings based on bioinformatics and machine learning
|Computers in Biology and Medicine|2023|47
Clinical evidence of acupuncture and moxibustion for irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials
|Frontiers in Public Health|2022|28
The function of the gut microbiota–bile acid–TGR5 axis in diarrhea-predominant irritable bowel syndrome
|mSystems|2024|25
Shenling Baizhu Powder Alleviates TNBS-Induced Colitis in Rats by Improving Intestinal Epithelial Permeability and Inhibiting Inflammation Through the TLR5/MyD88/NF-κB Pathway
|Frontiers in Pharmacology|2022|18